详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

Asia Pacific perspectives on the second year of the COVID-19 pandemic: A follow-up survey

5| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Pediatrics, Nippon Medical School, Tokyo, Japan [2]Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore [3]Division of Allergy and Immunology, Department of Pediatrics, University of the Philippines-Philippine General Hospital, Manila, Philippines [4]Allergy, Immunology, and Microbiome (A.I.M.) Research Centre, China Medical University Children's Hospital, Taichung, Taiwan [5]Allergy & Immunology Centre Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia [6]Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong, Hong Kong [7]Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, Hong Kong [8]Philippine Childrens Medical Center Hospital of Infant Jesus Medical Center, Fe del Mundo Medical Center, Quezon City, Philippines [9]Department of Clinical Immunology, Sir Charles Gairdner Hospital, Perth Children's Hospital, Perth, WA, Australia [10]Medical School, University of Western Australia, Perth, WA, Australia [11]Department of Pediatrics, Hanyang University Guri Hospital, Guri, South Korea [12]Pediatric Allergy and Immunology, Samitivej Children's Hospital, Bangkok, Thailand [13]National Hospital Organization Mie National Hospital, Institute for Clinical Research, Tsu, Japan [14]Division of Allergy and Clinical Immunology, Department of Internal Medicine, Cipto Mangunkusumo General Hopsital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia [15]P.D. Hinduja National Hospital and Medical Research Centre, Breach Candy Hospital, in Mumbai, Mumbai, India [16]CMRI Hospital, Kolkata, India [17]Department of Pulmonology and Allergology, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia [18]Department of Biochemistry, School of Biomedicine, National University of Medical Sciences, Ulaanbaatar, Mongolia [19]Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam [20]Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China [21]Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China

出处：

DOI：

ISSN：

关键词： anaphylaxis endemic diseases prophylaxis therapeutics vaccination

摘要：

The Coronavirus disease 2019 (COVID-19) pandemic is currently in its third year. This follow-up survey was commissioned by the Asia Pacific Association of Allergy Asthma and Clinical Immunology (APAAACI) Task Force on COVID-19 to compare and contrast changes in the epidemiology, clinical profile, therapeutics and public health measures of the pandemic in the Asia Pacific region.A questionnaire-based survey comprising 32 questions was electronically sent out to all 15 member countries of APAAACI using Survey Monkey® from 1 December 2021 to 28 February 2022.Seventeen responses were received from 14/15 (93.4%) member countries and 3 individual members. Mild-to-moderate COVID-19 predominated over severe infection, largely contributed by COVID-19 vaccination programmes in the region. The incidence of vaccine adverse reactions in particular anaphylaxis from messenger ribonucleic acid (mRNA) vaccines was no longer as high as initially anticipated, although perimyocarditis remains a concern in younger males. Novel therapeutics for mild-to-moderate disease including neutralizing antibodies casirivimab/imdevimab (REGEN-COV®) and sotrovimab (Xevudy®), anti-virals Paxlovid® (nirmatrelvir and ritonavir) and Molnupiravir pre-exposure prophylaxis for high-risk persons with Tixagevimab and Cilgavimab (Evusheld) are now also available to complement established therapeutics (e.g., remdesivir, dexamethasone and baricitinib) for severe disease. In the transition to endemicity, public health measures are also evolving away from containment/elimination strategies.With access to internationally recommended standards of care including public health preventive measures, therapeutics and vaccines among most APAAACI member countries, much progress has been made over the 2-year period in minimizing the morbidity and mortality from COVID-19 disease.© 2022 John Wiley & Sons Ltd.

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 2 区医学

小类 | 2 区过敏 2 区免疫学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区过敏 2 区免疫学

JCR分区：

出版当年[2020]版：

Q2 IMMUNOLOGY Q2 ALLERGY

最新[2023]版：

Q1 ALLERGY Q1 IMMUNOLOGY

影响因子： 6.3 最新[2023版] 5.2 最新五年平均 5.018 出版当年[2020版] 5.247 出版当年五年平均 4.217 出版前一年[2019版] 5.401 出版后一年[2021版]

第一作者：

第一作者机构： [1]Department of Pediatrics, Nippon Medical School, Tokyo, Japan [*1]Department of Pediatrics, Nippon Medical School, Tokyo, Japan.

共同第一作者：

通讯作者：

通讯机构： [1]Department of Pediatrics, Nippon Medical School, Tokyo, Japan [*1]Department of Pediatrics, Nippon Medical School, Tokyo, Japan.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Asia Pacific perspectives on the second year of the COVID-19 pandemic: A follow-up survey

文献详情

相关文献